Sulinno (adalimumab biosimilar) / Innovent Biologics - LARVOL DELTA

Comparative real-world retention rate and safety of biosimilar IBI303 versus Humira in ankylosing spondylitis: A retrospective study. (PubMed, Medicine (Baltimore)) - "However, the Humira group had significantly higher median costs in the first year than the IBI303 group (P = .004). In conclusion, in Chinese AS patients, there is no difference in retention rate and safety between generic and brand-name adalimumab in real-world use, but IBI303 is the more cost-effective choice."

Clinical • Journal • Observational data • Real-world evidence • Retrospective data • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications (PRNewswire) - "Innovent Biologics, Inc...announced that, five products (including new indications) of the company have been included in the updated National Reimbursement Drug List (2022 Version) ('NRDL')....SULINNO® (adalimumab injection): A total of eight approved indications (including two new indications) have been included in the NRDL for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, crohn's disease (new indication) and pediatric crohn's disease (new indication)."

Reimbursement • Ankylosing Spondylitis • Crohn's disease • Immunology • Inflammatory Bowel Disease • Psoriasis • Rheumatoid Arthritis

"Innovent’s Sulinno (Adalimumab biosimilar) Receives China’s NMPA Approval for Pediatric Plaque Psoriasis and Non-infectious Uveitis @Pharmashot https://t.co/EDOIVNmjg7" (@Pharmashot)

Clinical • Complement-mediated Rare Disorders • Dermatology • Immunology • Ocular Inflammation • Ophthalmology • Pediatrics • Psoriasis • Uveitis

NMPA accepts biosimilar New Drug Application for IBI303, a biosimilar candidate to Humira (adalimumab) (PRNewswire) - "Innovent Biologics...announced today that National Medical Products Administration (NMPA, successor to CFDA) has accepted its new drug application (NDA) for adalimumab biosimilar candidate (IBI303). IBI303 is a recombinant human anti-TNF-α monoclonal antibody independently developed by Innovent for the treatment of ankylosing spondylitis (AS), rheumatoid arthritis (RA) and psoriasis."

Non-US regulatory • Ankylosing Spondylitis • Immunology • Inflammation • Inflammatory Arthritis • Psoriasis • Rheumatoid Arthritis • Rheumatology

Biosimilar to Humira, IBI303, shows comparable efficacy and safety in phase 3 trial in China (Ankylosing Spondylitis News) - "In an accompanying comment in the same journal, 'Biosimilars for rheumatic diseases: China joins the club,' Stanley Cohen, MD...said the Phase 3 results 'support the approval' of IBI303."

Media quote